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Summary
Objectives: Nitric oxide (NO) is a major mediator of joint tissue inﬂammation and damage in osteoarthritis (OA) and mediates the nitration of
tyrosine (Y*) residues in proteins. We investigated the nitration of type III collagen, a major constituent of synovial membrane, in knee OA.
Methods: A polyclonal antibody directed against the nitrated QY*DSY*DVKSG sequence from type III collagen N-telopeptide was generated.
Synovial tissues from patients with knee OA (n¼ 4) and rheumatoid arthritis (RA, n¼ 4) were analyzed by immunohistochemistry for IIINys.
Serum IIINys levels were measured by enzyme-linked immunosorbent assay in 87 patients with painful knee OA (mean age: 63.0 8.0 years,
KellgreneLawrence score IIeIII) and in 40 sex and age-matched healthy controls.
Results: Competition experiments using various nitrated and un-nitrated type III collagen and derived sequences, showed that the antibody
was highly speciﬁc for the nitrated IIINys sequence. High IIINys immunoreactivity was detected in the synovial tissues from all patients with OA
and RA with a preferential localization in the intimal layer. Serum IIINys levels were on average 1.5-fold higher (P< 0.0001) in patients with
knee OA than in healthy controls and signiﬁcantly correlated with C-reactive protein values (r¼ 0.40, P< 0.005).
Conclusions: Nitration of tyrosine residues of type III collagen N-telopeptide is increased in the synovial tissue of patients with knee OA. Mea-
surements of serum IIINys level may be useful for the clinical investigation of oxidative-related alterations of synovial tissue metabolism in OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common joint disease involving
a cascade of catabolic events that ultimately lead to abnor-
mal and degraded articular tissues. Although OA has been
considered as a non-inﬂammatory disease, mild to moder-
ate inﬂammatory changes are also seen in OA synovial tis-
sue at certain stages of the disease1. Arthroscopic
evaluations of knee joint show that about 25% of subjects
with painful knee OA have inﬂamed synovial tissue and
these patients are at increased risk for radiological progres-
sion2. Synovial tissue inﬂammation involved a complex net-
work of cytokines such as interleukin-1 (IL-1) and tumor
necrosis factor-a (TNF-a), but also other mediators includ-
ing nitric oxide (NO)3. NO is a free radical produced by a va-
riety of cells in joint tissues including macrophages,
synoviocytes, chondrocytes and osteoblasts4,5. NO levels
are increased under inﬂammatory conditions and induce cy-
totoxic effects through the creation of oxidative stresses6.
The reaction of NO with superoxide-producing peroxini-
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1362resulting in the formation of the posttranslational modiﬁed
nitrotyrosine7. Using antibodies raised against nitrotyrosine
residues, it has been shown that joint tissues of patients
with OA, especially the synovial membrane, contain high
levels of nitrated proteins although the nature of the proteins
and the amino acid sequences involved has not been
characterized8,9.
Because of the pivotal role played by synovial tissue in-
ﬂammation in OA progression, developing biochemical
markers reﬂecting speciﬁcally synovium metabolism would
be extremely useful. Several serum biochemical markers
have been suggested to assess this process including se-
rum C-reactive protein (CRP) e an unspeciﬁc systemic in-
ﬂammation marker e and serum hyaluronic acid which is
secreted by synoviocytes but also by other tissues including
the liver10. Recently attempts been undertaken to develop
biochemical markers reﬂecting more speciﬁcally synovial
tissue metabolism based on the detection of posttransla-
tional modiﬁcations of the extracellular collagen molecules.
A glycosylated derivative of the collagen telopeptide cross-
link pyridinoline, namely glucosyl-galactosyl-pyridinoline
(Glc-Gal-PYD), has been detected in large amounts in hu-
man synovial tissue11 and urinary Glc-Gal-PYD levels
have been reported to be signiﬁcantly increased in patients
with knee OA12,13. However this marker does not distin-
guish between type I and type III collagen e which are
the two major proteins of synovial tissue e and its
1363Osteoarthritis and Cartilage Vol. 17, No. 10measurement, is currently impaired by the cumbersome
high performance liquid chromatography required for its de-
tection in urine.
Within the N-telopeptide of type III, we have identiﬁed
the sequence QYDSYDVKSG (IIINys) which contains two
tyrosine residues (Y) that we hypothesized could to be ni-
trated in OA (Fig. 1). The aims of this study were (1) to in-
vestigate whether this sequence was nitrated in the
synovial tissue of patients with OA, (2) develop an en-
zyme-linked immunosorbent assay (ELISA) for its quantita-
tive measurement in circulating blood and (3) perform
a preliminary clinical evaluation by comparing serum IIINys
levels between patients with knee OA and healthy
individuals.Materials and methodsTISSUE MATERIALSSynovial tissue specimens were obtained during knee replacement from
patients with knee OA, rheumatoid arthritis (RA) and non-arthritic controls.
They were immediately ﬁxed, dehydrated, embedded in parafﬁn and stored
until immunohistochemistry. The protocols for obtaining synovial tissue were
reviewed and approved by local ethic committees.
Patients with knee OA patients (n¼ 4) were postmenopausal women (age
range: 54e73 years) diagnosed with primary OA according to the American
College of Rheumatology criteria (ACR14) who did not suffer from other
bone-related, endocrinological or metabolic diseases at the time of examina-
tion. Patients scored 3e5 on the Ahlba¨ck scoring system15.
Patients with RA (n¼ 4) were postmenopausal women (age range:
44e72 years) who meet ACR criteria of RA16.
Control synovial tissue was obtained from the knee joint of two subjects (a
woman and a man of 65 and 29 years old, respectively) with aseptic osteo-
necrosis, a non-arthritic disease. A biopsy of femoral muscle e a tissue com-
prising type III collagen e from a patient with muscle cyst was also used as
a control.PATIENTS WITH KNEE OA AND HEALTHY CONTROLSFasting morning serum samples were collected before 10 am and stored
frozen at 70C until assay.
Patients with knee OA
Eighty-seven patients (73% women; mean standard deviation (SD):
age: 63 8 years, body mass index (BMI): 30.0 4.5 kg/m2, disease dura-
tion: 6.1 6.8 years), years meeting ACR criteria14 were investigated. These
patients were randomly selected from a total of 537 patients with knee OAFig. 1. Structure of the aminoterminal telopeptide of type III collagen
and localization of the IIINys sequence. Type III collagen is a homo-
trimer of three a1(III) chains adopting a triple helical conformation,
except at the two ends in the telopeptide regions. Telopeptides are
linear part of the a chain containing the sites essential for intermo-
lecular cross-linking in extracellular matrix, including in synovial
tissue.participating in a randomized, multicenter, double-blind study of an investiga-
tional drug previously described17. All patients had pain in or around the knee
most of the time and less than 30 min of morning stiffness and had also ra-
diographically conﬁrmed osteophytes of the knee of grade 2 or 3 according
to the KellgreneLawrence scale. All subjects had a normalized total Western
Ontario and McMaster University OA index (WOMAC) score 50 mm on
a 100 mm visual analog scale (VAS). In this analysis only baseline samples,
before initiating any therapy were analyzed.
Healthy controls
Forty healthy postmenopausal women with a meanSD age of
63.2 3.67 years (range 58e73 years) were used as controls. All subjects
were healthy without any disease or treatment that could interfere with
bone or joint metabolism, including hormone replacement therapy. They
were recruited from a blood donor program in Lyon, France.SERUM CRP LEVELSSerum CRP levels in patients with knee OA were determined by an immu-
noturbidimetric assay (Randox Laboratories Ltd., Crumlin, County Antrim,
UK) on a Konelab 20 analyzer (Thermo Scientiﬁc, Cergy Pontoise, France).
The intra- and inter-assay coefﬁcients of variation (CVs) are lower than 5%
and the lower limit of quantiﬁcation is 2 mg/L.CHEMICALSAll chemicals were purchased as analytic grade from Sigma (St. Quentin
Fallavier, France), Merck (Limonest, France) or Euromedex (Strasbourg,
France). Synthetic peptides were synthesized to 85% purity by Epitop
(Nıˆmes, France)18.IIINys ANTIBODYRabbits were injected intraperitoneally with the synthetic peptide QY*D-
SY*DVKSG (where Y* is 3-nitrotyrosine) derived from the sequence of hu-
man N-telopeptide of type III collagen (SwissProt accession no. P02461)19
coupled with Keyhole Limpet Hemocyanin (KLH). The speciﬁcity of IIINys an-
tibody was investigated by competitive inhibition experiments using the fol-
lowing compounds: free 3-nitrotyrosine, nitrated bovine serum albumin
(BSA), native and nitrated intact human type III collagen (Euromedex,
France), the IIINys synthetic peptide extended with one amino acid at the
N-terminal end (PQY*DSY*DVKSG), the IIINys synthetic peptides containing
only one nitrated (QY*DYDVKSG and QYDSY*DVKSG) tyrosine residue or
the un-nitrated (QYDSYDVKSG) form. Nitration of intact type III collagen was
performed as previously reported20.IMMUNOHISTOCHEMISTRYSections of synovial tissue and muscle were cut from parafﬁn-embedded
blocks. Slices were incubated in xylene to remove parafﬁn and rinsed in eth-
anol. They were then incubated in 0.45% H2O2 in 99% ethanol for 30 min at
room temperature (RT) to inhibit endogenous peroxidase activity. Non-spe-
ciﬁc sites were blocked in 0.5% casein in Tris buffer saline (TBS). The IIINys
antibody or the non-immune anti-serum from the same rabbit [dilution
1:1000] was incubated with the synovial tissue slides overnight at 4C.
DAB (diaminobenzidine, Dako, Denmark) staining was enhanced by dipping
tissue slides in CuSO4. Lastly, sections were rinsed in H2O and counter-
stained with Mayer’s acidic hematoxylin.IIINys ELISAGoat anti-rabbit immunoglobulin G (IgG) antibody (Jackson ImmunoRe-
search Laboratory, West Grove, USA) diluted in phosphate buffer saline
(PBS) (1.5 mmol/L KH2PO4, 8.5 mmol/L Na2HPO4, 2.7 mmol/L KCl,
137 mmol/L NaCl, pH 7.4) was pipetted into microtiter plate wells (Maxi-
sorp, Nunc, Roskilde, Denmark) and incubated overnight at þ4C. The
plate was washed with PBS and blocked with PBS/BSA 3% for 2 h at
RT. After washing with assay buffer (TBS, BSA 0.5%, Tween 0.05%),
50 mL of biotinylated IIINys peptide, 50 mL of IIINys peptide used as calibra-
tors or serum samples (pre-diluted 1/3) and 100 mL of IIINys antibody
(1:10,000 dilution) were incubated for 2 h at RT. Peroxidase-conjugated
streptavidin (Beckman Coulter, Fullerton, USA) was then added for
30 min at RT. After washing, H2O2/tetramethylbenzidine substrate solution
(Interchim, Montluc¸on, France) was added to each well for 30 min at RT
and colorimetric reaction was stopped by the addition of 100 mL 0.5 M
H2SO4. The optical density (OD) at 405 nm corrected for the OD at
650 nm was measured.
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controls were analyzed using the non-parametric ManneWhitney test. Asso-
ciations between IIINys values and other quantitative variables were investi-
gated by non-parametric Spearman rank correlation.ResultsSPECIFICITY OF IIINys ANTIBODYThe speciﬁcity of the IIINys antibody was investigated
by competition analyses. As shown on Fig. 2, the binding
of the IIINys peptide on the antibody was not altered by
free 3-nitrotyrosine, nitrated BSA, native and nitrated in-
tact human type III collagen, the un-nitrated IIINys peptide
(QYDSYDVKSG) and the IIINys peptide extended by one
amino acid at the N-terminal end (PQY*DSY*DVKSG).
The antibody recognized with a very low afﬁnity the IIINys
peptide containing only the most C-terminal end nitrated
tyrosine residue (QYDSY*DVKSG). IIINys antibody recog-
nized the sequence where only the most N-terminal end
tyrosine residue was nitrated (QY*DSYDVKSG), although
to a lower afﬁnity than fully nitrated IIINys peptide.IMMUNOLOCALIZATION OF IIINys IN SYNOVIAL TISSUEFigure 3 shows representative immunohistochemistry of
synovial samples from patients with knee OA patients, pa-
tients with RA and non-arthritic controls. Similar ﬁndings
were observed for tissues of all patients with slight differ-
ences in the intensity of the staining.
Synovial tissue from patients with knee OA showed mild
morphologic changes with no evidence of inﬂammatory cell
inﬁltrate. Intense IIINys immunoreactivity was observed in
the intimal lining within the ﬁbrous tissue surrounding theFig. 2. Speciﬁcity of the ELISA for nitrosyled N-telopeptide of type III col
following competitors and the IIINys di-nitrated sequence (QY*DSY*DVK
(QYDSYDVKSG), the IIINys peptide extended by an amino acid at the N
the most N-terminal end tyrosine nitrated (QY*DSYDVKSG), the IIIN
(QYDSY*DVKSG), native and nitrated intact type III collagen, free 3-nitrot
of the biotinylated IIINys peptide on IIINys antibody coated on the microtite
a percentage of the binding with no competitor peptide (B0). The x-asynoviocytes [Fig. 3(b,c)]. IIINys immunoreactivity was
also found in the walls of blood vessels.
Synovial tissue from patients with RA showed evidence
of marked inﬂammation characterized by subintimal inﬁltra-
tion of synoviocytes and inﬂammatory cells, lymphoid ag-
gregation, neovascularization and ﬁbrosis. Fibrous tissue
surrounding synoviocytes in the intimal lining showed
strong IIINys immunoreactivity [Fig. 3(e,f)]. In the sublining
layer, cell inﬁltrate, synoviocytes, macrophages and lym-
phoid aggregates also showed intra- and peri-cellular IIINys
immunoreactivity. IIINys immunoreactivity was also de-
tected in the sublining wall vessels as observed in OA syno-
vial tissues.
In the synovial tissue of subjects with a non-arthritic dis-
ease and in the skeletal muscle, no signiﬁcant IIINys immu-
noreactivity was detected [Fig. 3(gei)].
In all tissue samples, no staining was observed with the
pre-immune anti-serum used as a negative control
[Fig. 3(a, d, g and j)].ANALYTIC PERFORMANCE OF THE IIINys ELISAThe IIINys ELISA utilizes the synthetic IIINys peptide as
a standard at different concentrations and a typical standard
curve is shown on Fig. 4. The lower limit of detection, deﬁned
as the concentration corresponding to two SDs above the
mean of 20 determinations of the zero calibrator, was deter-
mined to be 1.04 mg/L. Analytical intra (25 determinations in
the same run) and inter-assay (10 different runs) CVs as-
sessed by repeated measurements of three different serum
samples (mean levels: 3.83, 23.64 and 42.36 mg/L) ranged
from 7.8 to 14.5% and from 8.5 to 14.5%, respectively. Line-
arity of the assay was tested by performing serial dilutions of
serum samples in assay buffer. Themedian dilution recovery
of two samples (one from a patient with knee OA and onelagen (IIINys). The graph shows the inhibition curves between the
SG) for the binding to the antibody: the non-nitrated IIINys peptide
-terminus (PQY*DSY*DVKSG), the IIINys peptide containing only
ys peptide with only the most C-terminal end tyrosine nitrated
yrosine (Y*) and nitrated BSA. The y-axis shows the relative binding
r plate at different concentrations of each peptide (B) expressed as
xis shows the molar concentration of each competitor peptide.
Fig. 3. Immunolocalization of IIINys in the knee synovial tissue of a non-arthritic control, a patient with RA and a patient with OA and in the
skeletal muscle of a patient with muscle cyst. A brown color indicates positive immunoreactivity. The blue nuclear counterstain/staining is May-
er’s hematoxylin. Histological features of synovium are indicated as follow: adipose tissue (A), intimal lining (I), lymphoid aggregates (L), blood
vessels (V). (aec) Knee synovial tissue from a patient with knee OA showing positive IIINys immunoreactivity (b and c) around synoviocytes in
the lining cells and in wall vessels (arrows). Non-immune serum was used as negative control (a). (def) Knee synovial tissue from a patient
with RA showing positive IIINys immunoreactivity (e and f) around synoviocytes in intimal lining, in cells inﬁltrates, lymphoid aggregates and
vessel wall (arrows). (gei) Knee synovial tissue from a non-arthritic control, showing negative immunoreactivity with non-immune serum (g)
and IIINys anti-serum (h and i). (jek) Skeletal muscle showing no IIINys immunoreactivity (j and k).
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curves were parallel to the standard curve (Fig. 4).
Stability of serum IIINys was assessed on four different
samples. Serum IIINys levels remained stable after incuba-
tion for up to 24 h at þ4C, up to 6 h at RT and after four
repeated freezeethaw cycles (data not shown).SERUM IIINys LEVELS IN PATIENTS WITH KNEE OA AND
HEALTHY INDIVIDUALSIn healthy postmenopausal women and in patients with
knee OA analyzed together or separately, serum IIINys
did not correlate signiﬁcantly with age. In patients with
knee OA there was no signiﬁcant difference between post-
menopausal women (n¼ 63, mean age of 63.3 years) and
men of similar age (n¼ 24, mean age of 64.1 years). As
shown on Fig. 5, compared to healthy sex andage-matched controls, the median circulating IIINys levels
were 47% higher in patients with knee OA (P< 0.01)
(7.82 vs 5.32 ng/mL). There were 34% of individual pa-
tients with knee OA presenting with IIINys levels above
the upper limit of controls (deﬁned as the 95th percentile).
There were 69% of patients who had CRP values at or be-
low the lower limit of the quantiﬁable range of the assay
(2 mg/L) and for whom we assigned a value of 2 mg/L.
When all patients with knee OA were considered (with
values above or below the lower limit of quantiﬁcation),
IIINys levels only modestly correlated with CRP values
(r¼ 0.40, P< 0.005). When patients with CRP values at
or below 2 mg/L were excluded, IIINys levels also signiﬁ-
cantly correlated with CRP values (r¼ 0.55, P< 0.01)
(Fig. 6). When the two patients with the highest IIINys
levels were excluded, the correlation remained signiﬁcant
(r¼ 0.47, P¼ 0.037). IIINys levels did not correlate with
Fig. 6. Relationship between serum CRP and IIINys levels in pa-
tients with knee OA presenting with CRP values greater than the
quantiﬁcation limit. r and P are values of the correlation coefﬁcient
and signiﬁcance level, respectively from Spearman rank analyses.
Fig. 4. Typical standard curve using IIINys synthetic peptide as
a standard and dilution of two serum samples from control individ-
ual and a patient with OA.
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posed as a non-speciﬁc biochemical marker of synovial tis-
sue turnover (r¼0.025, P¼ 082). IIINys levels did not
correlate with the total WOMAC score and its pain, function
and stiffness subscales.Discussion
In this study we showed that the IIINys sequence of the
N-telopeptide of type III collagen e a major constituent ofFig. 5. Serum IIINys levels in healthy controls and in patients with
knee OA. The solid horizontal lines with the associated values rep-
resent the median IIINys level of each group (mg/L). The dotted
lines represent the upper limit in healthy controls (95th percentile).
Circles in gray represent knee OA patients with IIINys levels above
the upper limit in healthy controls. P values were determined by
non-parametric ManneWhitney rank test.synovial membrane e is nitrated in patients with OA and
RA. Serum IIINys levels are increased in patients with
knee OA and modestly correlated with CRP, a non-speciﬁc
marker of systemic inﬂammation.
Our competition experiments showed that the immunore-
activity of the type III collagen fragments detected by the
IIINys antibody is dependent on the presence of both a spe-
ciﬁc sequence within the N-telopeptide and the nitration of
its two tyrosine residues. The homology between the IIINys
peptide and its corresponding sequence in human type I
collagen e the major protein of bone tissue e is only 50%
and it does not contain the most N-terminal tyrosine residue
which is critical for antibody recognition. Thus, cross-reac-
tivity of IIINys antibody with type I collagen is unlikely.
Cross-reactivity of IIINys antibody with cartilage type II col-
lagen is also unlikely because the sequence homology is
only 30% and type II collagen N-telopeptide does not con-
tain tyrosine residues.
We immunolocalized the IIINys sequence in the synovial
tissue of patients with RA and more speciﬁcally in areas pre-
senting with histological signs of inﬂammatory activity. A sim-
ilar immunolocalization was observed in OA synovium with
however a lower intensity consistent with the mild inﬂamma-
tory component of this tissue. Both in the synovial tissue of
patients with OA and RA, IIINys immunoreactivity was local-
ized within the cells and in the surrounding extracellular ma-
trix. The presence of IIINys in the matrix close to the
synoviocytes, macrophages and neutrophils can be ex-
plainedby the release of reactive-species by these cells lead-
ing to the nitration of the surrounding extracellular type III
collagen molecules. The immunolocalization of IIINys within
macrophages is consistent with previous reports showing in-
creased expression of free nitrotyrosine and NO-modiﬁed
proteins in these cells8,9. In contrast, we could not detect
any signiﬁcant IIINys immunoreactivity in the synovial mem-
brane of non-arthritic patients and in the skeletal muscle of
patients with cyst resulting from rupture or ﬁbrosis, providing
further support to the speciﬁcity of the staining.
We developed an ELISA for serum IIINys that demon-
strated adequate analytical performances in terms of preci-
sion, accuracy and sensitivity. Using this ELISA we found
that IIINys levels were signiﬁcantly higher in patients with
knee OA that in healthy age-matched controls, but only
1367Osteoarthritis and Cartilage Vol. 17, No. 1034% of subjects had values above the upper limit of con-
trols. Large overlap in levels between OA patients and
healthy individuals has been consistently reported for other
biochemical markers of bone, cartilage and synovial tis-
sue10,12, reﬂecting the natural heterogeneity of the disease.
This also indicates that the assessment of any currently
available biochemical marker, including IIINys cannot be
used alone to diagnose OA.
We recently reported that IIINys levels were 3-fold higher
than control values in patients with active RA and a vast
majority of them (83%) had values above the upper limit
of the controls21. These data are consistent with the immu-
nohistochemistry ﬁndings of our current study showing
more intense IIINys staining in RA than OA synovial tissue.
In patients with knee OA, IIINys levels modestly correlated
with serum CRP, a non-speciﬁc biological marker of sys-
temic inﬂammation, in agreement with our previous study
in RA21. The extent of this association is of similar magni-
tude to that reported for other proposed biological markers
of synovial tissue metabolism, including Glc-Gal-PYD both
in patients with knee OA12 and RA13. IIINys levels did not
correlate signiﬁcantly with disease activity scores both in
OA and RA21, a ﬁnding also observed previously with other
biological joint tissue remodeling markers13. The rather nar-
row range of WOMAC score (>50 mm VAS for all subjects)
may have limited the power to detect such a relationship.
Our study has some limitations. The biochemistry of NO-
mediated inﬂammation and nitration of proteins is complex
involving various biological pathways, several reactive-spe-
cies and different cell types in joint tissues. It has also been
shown that nitrotyrosine increases in human and monkey
cartilage not only with OA, but also with aging22,23. Interest-
ingly, it has recently been reported that speciﬁc sequences
within the helicoidal part of type II collagen e the major pro-
tein of cartilage matrix e can also be nitrated in human OA
cartilage24. Higher serum levels of nitrated type II collagen
were reported in patients with OA, but did not change with
age, consistent with the ﬁndings we obtained with IIINys25.
Consequently it remains to be investigated the exact mech-
anisms involved in the generation of IIINys within the syno-
vial tissue and the potential factors that may inﬂuence its
level such as aging. Because the number of synovial tissue
samples investigated for immunolocalization studies was
limited and did not include older controls, this issue needs
to be investigated in further larger studies including
a wide age range.
From a clinical standpoint, we found that serum IIINys
levels were increased on average in patients with estab-
lished knee OA. It remains to be investigated whether se-
rum IIINys can detect increased NO-mediated synovial
tissue alterations in patients with early OA and to analyze
its ability to predict disease progression and to monitor
treatment efﬁcacy, including NO targeted therapies.Conﬂict of interest
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